Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company’s product include CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product. Its products also comprise Treximet, a medication indicated for the acute treatment of migraine attacks in adults; Silenor, a medication indicated for the treatment of insomnia characterized by difficulty with sleep maintenance; Khedezla, a prescription medication for major depressive disorder. In addition, the company offers various generic pharmaceutical products in the areas of nutritional supplements, analgesics, urinary tract, women’s health, pre-natal vitamins, and dental health, as well as allergy, respiratory, iron deficiency, nephrology, and pain management. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. The company was founded in 1996 and is headquartered in Morristown, New Jersey.